SCHEMBL20183789

SCHEMBL20183789

CCn1c(=O)cc(N2CCOCC2)c2cc(-n3c(-c4ccccc4)cn(CCN4CCOCC4)c3=O)ccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.39
CREBBP Q92793 1/20 0.39
PTGER4 P35408 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
NPY5R Q15761 1/20 0.37
HSD17B10 Q99714 3/20 0.36
KDM4E B2RXH2 3/20 0.36
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
GAA P10253 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPK1 P28482 2/20 0.36
TSHR P16473 1/20 0.36
LYN P07948 1/20 0.36
SRC P12931 1/20 0.36
METAP2 P50579 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20354312 0.96 KDM4E (0.36) BRD4CREBBPPTGER4MEN1KMT2A
SCHEMBL20354313 0.94 KDM4E (0.37) BRD4CREBBPMEN1KMT2AHSD17B10
SCHEMBL20788143 0.93 KDM4E (0.38) BRD4CREBBPMEN1KMT2AHSD17B10
SCHEMBL20806267 0.92 KDM4E (0.38) BRD4MEN1KMT2AHSD17B10KDM4E
SCHEMBL20183845 0.92 KDM4E (0.38) BRD4CREBBPPTGER4MEN1KMT2A
SCHEMBL20788145 0.91 KDM4E (0.37) BRD4CREBBPMEN1KMT2AHSD17B10
SCHEMBL20183575 0.91 HSD17B10 (0.39) BRD4PTGER4MEN1KMT2AHSD17B10
SCHEMBL20183610 0.85 KDM4E (0.37) BRD4MEN1KMT2AHSD17B10KDM4E
SCHEMBL20183530 0.82 BRD4 (0.38) BRD4PTGER4MEN1KMT2AHSD17B10
SCHEMBL20183815 0.81 GAA (0.40) BRD4MEN1KMT2AHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US disclosed
EP-3327004-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORP (JP) 2020-11-04 EP disclosed
US-10696637-B2 Nitrogen-containing heterocyclic compound FUJIFILM CORPORATION (JP) 2020-06-30 US disclosed
US-10696637-B2 Nitrogen-containing heterocyclic compound FUJIFILM CORPORATION (JP) 2020-06-30 US disclosed
US-10633343-B2 2020-04-28 US disclosed
US-10633343-B2 2020-04-28 US disclosed
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORPORATION (JP) 2019-10-17 US disclosed
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORPORATION (JP) 2019-03-14 US disclosed
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORPORATION (JP) 2019-03-14 US disclosed
EP-3327004-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Fujifilm Corporation (JP) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987349-B2 Antitumor agent and bromodomain inhibitor BRD4, BRD1, BRD3 BRD4 1/4885CREBBP 197/4885PTGER4 3214/4885
US-10696637-B2 Nitrogen-containing heterocyclic compound CXCL10, CCL5, CXCR3 BRD4 238/4885CREBBP 336/4885PTGER4 3686/4885
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR BRD4, BRD1, BRD3 BRD4 1/4885CREBBP 197/4885PTGER4 3214/4885
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CXCL10, CCL5, CXCR3 BRD4 238/4885CREBBP 336/4885PTGER4 3686/4885
US-10633343-B2 CXCL10, CCL5, CXCR3 BRD4 496/4885CREBBP 260/4885PTGER4 3588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.